TEMPUS FORGES STRATEGIC PARTNERSHIP WITH GILEAD TO ENHANCE ONCOLOGY RESEARCH AND DEVELOPMENT USING REAL-WORLD EVIDENCE

Written by Emily J. Thompson, Senior Investment Analyst

Source: moomoo

Updated: Apr 09 2026

0mins

TEM+2.66%

GILD-0.66%

Should l Buy TEM?

Source: moomoo

Strategic Collaboration Announcement: Tempus has announced a strategic collaboration with Gilead to enhance research and development in oncology.
Focus on Oncology R&D: The partnership aims to advance oncology research and development through innovative approaches and shared expertise.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy TEM?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on TEM

Wall Street analysts forecast TEM stock price to rise

9 Analyst Rating

4 Buy

5 Hold

0 Sell

Moderate Buy

Current: 54.420

Low

76.00

Averages

84.38

High

105.00

Current: 54.420

Low

76.00

Averages

84.38

High

105.00

TD Securities

Hold

Buy

upgrade

$70 -> $65

2026-04-13

Reason

TD Securities

Price Target

$70 -> $65

AI Analysis

2026-04-13

upgrade

Hold

Buy

Reason

TD Securities upgraded Tempus AI to Buy from Hold with a price target of $65, down from $70. The shares are down over 50% in the last six months while the company's fundamentals have strengthened, the analyst tells investors in a research note. TD believes Tempus AI's Insights business is well positioned to accelerate growth in 2026 and benefit from pharma's increased demand for AI research and development offerings. In addition, the company's genomics growth momentum should continue, adds the firm. TD says Tempus AI's AI risk is overdone in the share price, creating an attractive valuation.

Jefferies

Underperform

initiated

$35

2026-04-12

Reason

Jefferies

Price Target

$35

2026-04-12

initiated

Underperform

Reason

Jefferies initiated coverage of Tempus AI with an Underperform rating and $35 price target. The firm sees \"secular tailwinds\" in the oncology diagnostics space from improving therapies and declining sequencing costs, but also \"ongoing polarization between the leaders and laggards.\" Jefferies is cautious on Tempus due to concerns on its data business and reimbursement. The company has an \"unclear catalyst path\" in diagnostics, as it lacks a \"true step-function catalyst similar to peers,\" contends Jefferies.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TEM

Unlock Now

About TEM

Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Tempus and Predicta Launch Co-Branded Genomic Sequencing Assay

4 days agoNewsfilter

Joint Launch of New Assay: Tempus AI and Predicta Biosciences announced the commercial expansion of the GenoPredicta™ genomic sequencing assay, aimed at comprehensive characterization of hematologic malignancies and measurable residual disease (MRD) monitoring, significantly enhancing diagnostic accuracy in clinical settings.
Ultra-High Sensitivity: The GenoPredicta assay extracts deep genetic insights from as few as 50 tumor cells, achieving a sensitivity as low as one in a million, which expands testing eligibility to cases with low tumor burden, thereby increasing treatment opportunities for patients.
Integrated Technology Advantage: By combining flow cytometry with whole-genome sequencing, the assay delivers 100% concordance between peripheral blood and bone marrow, sparing patients from invasive biopsies while providing researchers with deeper insights into disease biology.
Accelerated Market Adoption: Predicta's CEO stated that this partnership with Tempus will accelerate market adoption and optimize the utility of clinical trials, further advancing the development of precision medicine and enabling smarter treatment decisions for physicians.

Tempus AI Announces 31 Abstracts for AACR Annual Meeting 2026

5 days agoNewsfilter

Research Highlights: Tempus AI will present 31 abstracts, including one oral presentation, at the 2026 AACR Annual Meeting, emphasizing the real-world impact of its multimodal datasets and AI diagnostic solutions, which are expected to transform cancer diagnosis and treatment.
Gene Fusion Insights: In a study of 30,884,099 colorectal cancer patients, the co-occurrence of microsatellite instability (MSI) and gene fusions was significantly enriched in MSI tumors at 6.2% compared to 2.2% in MSS tumors, providing new stratification criteria for clinical treatment.
Clinical Significance of KMT2C Mutations: The analysis revealed that patients with KMT2C mutations had a real-world overall survival (rwOS) of 19.6 months post-platinum chemotherapy, compared to 16.7 months for non-mutated patients, with colorectal cancer patients showing a median rwOS of 51.0 months, highlighting its potential as a predictive biomarker.
Machine Learning in SCLC: The research team developed a machine learning model analyzing genomic and transcriptomic data from approximately 1,400 small cell lung cancer patients, finding that nearly 30% of those with RB1 genomic alterations still exhibited RB function, challenging traditional beliefs and potentially influencing future treatment strategies.

Latest Wall Street Ratings Overview

6 days agoCNBC

Tesla Rating Maintained: Wells Fargo reiterates its underweight rating on Tesla ahead of earnings, indicating a cautious outlook due to limited progress on Robotaxi and Optimus, suggesting a strategic pivot towards Semi and Roadster could be necessary for future growth.
Starbucks Rating Upgrade: Jefferies upgrades Starbucks from sell to hold, citing stabilization in the U.S. market, and while the stock trades at a high premium, the expectation of more realistic earnings estimates reflects a more optimistic view on the company's future performance.
Nokia Transformation: Bank of America upgrades Nokia from neutral to buy, highlighting its transition into an optical powerhouse, which positions the company favorably in the telecom equipment market and suggests significant growth potential ahead.
Chime Financial Rating Initiated: Wells Fargo initiates coverage on Chime Financial with an overweight rating, recognizing its strong growth and profitability in the digital banking sector, and anticipates a positive impact from the upcoming tax season.

Tempus Launches Automated Clinical Update Service for Precision Medicine

6 days agoNewsfilter

Automated Clinical Updates: Tempus AI has launched an automated clinical update service designed to place patients on an 'active follow-up' track, ensuring they receive the latest treatment recommendations throughout their care journey, thereby enhancing evidence-based clinical decision-making.
Real-Time Update Mechanism: This service automatically surfaces updated therapy recommendations when clinical guidelines change or new therapeutic options emerge, eliminating the need for new patient samples, which significantly improves the timeliness and effectiveness of patient treatment.
Addressing Rapid Changes: Chief Medical Officer Ezra Cohen noted that the pace of drug approvals and treatment changes in modern oncology far exceeds previous rates, and Tempus's service aims to bridge the gap between genomic sequencing and drug approval, ensuring genomic insights remain current.
Vision for Precision Medicine: Tempus is committed to advancing precision medicine through its extensive multimodal data library and AI-driven solutions, ensuring that each patient benefits from the treatment experiences of others, thus enhancing the quality of personalized care.

Tempus Expands Collaboration with Gilead to Enhance Oncology Pipeline

Apr 09 2026Newsfilter

Collaboration Expansion: Tempus AI has announced a multi-year expanded collaboration with Gilead Sciences aimed at advancing Gilead's oncology research and development through Tempus' multimodal data repository, enhancing the effectiveness of clinical decision-making.
Data-Driven Innovation: Gilead will gain enterprise-wide access to Tempus' AI-driven Lens platform, enabling the use of broader datasets for trial design and biomarker strategies, thereby accelerating the new drug development process.
Patient-Centric Goals: Patrick Loerch, SVP of Clinical Data Science at Gilead, stated that this partnership reflects a shared commitment to improving cancer care quality by combining scientific expertise with real-world data insights.
Technology Empowerment: Tempus CEO Ryan Fukushima emphasized that by providing multimodal data, Gilead's team will be better equipped to leverage AI insights, increasing the probability of successfully developing life-altering medicines and driving significant breakthroughs in oncology.